The regulatory plans for Alkermes and its controversial drug for treatment-resistant depression have been upended by the Food and Drug Administration.

On Monday, the FDA said it would not review the Alkermes drug, called ALKS-5461, because of “insufficient evidence of overall effectiveness,” the company said in a statement. The FDA told Alkermes that additional “well-controlled clinical trials” would need to be conducted for the drug to be resubmitted.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Not just this drug – selective reporting and all types of biases appear to operate for ALL psychiatric drugs. Some of these issues are exposed in the following articles:

    Lancee, M., et al. (2017), Outcome reporting bias in randomized-controlled trials investigating antipsychotic drugs, Translational Psychiatry, 7, e1232.

    Hengartner MP (2017) Methodological Flaws, Conflicts of Interest, and Scientific Fallacies: Implications for the Evaluation of Antidepressants’ Efficacy and Harm. Front. Psychiatry8:275.

    Also, the site promotes critical dialogue regarding these issues.

  • Correction: ITCI submission is based on two successful trials and one failed — not 1 successful and 1 failed

  • Maybe the gold standard is coming back, Alks. Treatment resistant depression is a non sequiter anyway. In the old days when actual psychiatrists treated depression they were usually able to find a combo that worked. Now that insurance cos have stiffed the shrinks, depression gets treated by primary care docs who don’t know jack s*it about depression, and when SSRI fails, they throw up their hands and declare the depression resistant. The best treatment for resistant depression is 20 to 30 zaps with the ECT machine.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy